Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Corvus Pharmaceuticals (CRVS) Stock Price

Media stories about Corvus Pharmaceuticals (NASDAQ:CRVS) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.2649691280206 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Corvus Pharmaceuticals (NASDAQ CRVS) traded up $0.16 during trading on Monday, reaching $11.37. 55,400 shares of the company traded hands, compared to its average volume of 107,181. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.19. analysts predict that Corvus Pharmaceuticals will post -2.82 earnings per share for the current fiscal year.

Several research firms have recently commented on CRVS. Wedbush reaffirmed an “outperform” rating and set a $26.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, August 8th. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Tuesday, November 7th. Finally, Credit Suisse Group raised shares of Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price target for the company in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $20.25.

In other news, CEO Richard A. Md Miller bought 10,000 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Monday, November 20th. The stock was bought at an average cost of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 46.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Insider Buying and Selling by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

What are top analysts saying about Corvus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corvus Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit